ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,112.50
-0.03%
Dow Jones
44,457.18
-0.20%
US Dollar vs MXN
20.28166
-0.03%
Brent Oil
75.565
0.57%
Bitcoin
93,834.88
-2.02%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) Noticias

OKYO

OKYO Pharma (OKYO)

OKYO Pharma Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:OKYO
FechaHoraFuenteTítuloSímboloCompañía
12/02/202506:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
12/02/202506:00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Officially Assigned USAN : UrcosimodNASDAQ:OKYOOKYO Pharma Ltd
31/01/202506:00GlobeNewswire Inc.OKYO Pharma Announces Chairman and CEO Acquire SharesNASDAQ:OKYOOKYO Pharma Ltd
29/01/202507:00GlobeNewswire Inc.OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second QuarterNASDAQ:OKYOOKYO Pharma Ltd
22/01/202506:00GlobeNewswire Inc.OKYO Pharma Receives $1.4 Million in Non-Dilutive FundingNASDAQ:OKYOOKYO Pharma Ltd
26/11/202406:00GlobeNewswire Inc.OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceNASDAQ:OKYOOKYO Pharma Ltd
30/10/202406:00GlobeNewswire Inc.OKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceNASDAQ:OKYOOKYO Pharma Ltd
23/10/202406:00GlobeNewswire Inc.OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
16/10/202406:00GlobeNewswire Inc.OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
10/09/202406:00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
27/08/202406:00GlobeNewswire Inc.OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
23/08/202408:00GlobeNewswire Inc.OKYO Pharma CEO Interview to Air on Bloomberg TVNASDAQ:OKYOOKYO Pharma Ltd
15/08/202411:13GlobeNewswire Inc.OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:OKYOOKYO Pharma Ltd
13/08/202415:30Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:OKYOOKYO Pharma Ltd
06/08/202406:00GlobeNewswire Inc.OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of UseNASDAQ:OKYOOKYO Pharma Ltd
31/07/202416:00Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:OKYOOKYO Pharma Ltd
11/07/202406:00GlobeNewswire Inc.OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101NASDAQ:OKYOOKYO Pharma Ltd
10/07/202406:00GlobeNewswire Inc.OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
08/05/202406:00GlobeNewswire Inc.OKYO Pharma Announces Participation in May 2024 Investor ConferencesNASDAQ:OKYOOKYO Pharma Ltd
30/04/202406:00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)NASDAQ:OKYOOKYO Pharma Ltd
08/04/202418:00GlobeNewswire Inc.OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024NASDAQ:OKYOOKYO Pharma Ltd
02/04/202406:00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryNASDAQ:OKYOOKYO Pharma Ltd
22/03/202406:00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101NASDAQ:OKYOOKYO Pharma Ltd
21/03/202406:00GlobeNewswire Inc.OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialNASDAQ:OKYOOKYO Pharma Ltd
20/03/202406:00GlobeNewswire Inc.OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventNASDAQ:OKYOOKYO Pharma Ltd
09/02/202406:36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
31/01/202406:00GlobeNewswire Inc.OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardNASDAQ:OKYOOKYO Pharma Ltd
08/01/202406:00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
05/01/202408:30GlobeNewswire Inc.OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024NASDAQ:OKYOOKYO Pharma Ltd
20/12/202316:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OKYOOKYO Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:OKYO

Su Consulta Reciente

COIN
AVAXUSD
Avalanche
NYSE
BAC
Bank of America
NYSE
VZ
Verizon Communications
CCOM
OILBRENT
Brent Oil
NYSE
KO
Coca Cola
AMEX
XLF
Financial Select Sector
FX
EURUSD
Euro vs US Dollar
AMEX
SPY
SPDR S&P 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
US30
US 30
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
TSLA
Tesla
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios